{"id":60274,"date":"2021-10-05T11:21:37","date_gmt":"2021-10-05T09:21:37","guid":{"rendered":"https:\/\/www.fedaiisf.it\/?p=60274"},"modified":"2021-10-05T19:12:01","modified_gmt":"2021-10-05T17:12:01","slug":"boehringer-ingelheim-italia-cede-la-sede-di-milano-a-coiva","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/boehringer-ingelheim-italia-cede-la-sede-di-milano-a-coiva\/","title":{"rendered":"Boehringer Ingelheim Italia sells the Milan office to Coima Sgr"},"content":{"rendered":"<p>Coima Sgr has completed the acquisition, through the Coima Opportunity Fund II, of a complex <img loading=\"lazy\" decoding=\"async\" class=\"wp-image-60275 alignright\" src=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2021\/10\/Albert_Boehringer_Portrait-didascalia.jpg\" alt=\"\" width=\"179\" height=\"252\" \/>real estate located in Milan, on the corner between Via Giovanni Lorenzini and Via Ercole Marelli, which includes 7 properties for a total commercial area of 19,500 square meters and which currently houses the Italian headquarters of the pharmaceutical multinational Boehringer Ingelheim. (\u2026 continue on <a href=\"https:\/\/www.ansa.it\/lombardia\/notizie\/2021\/10\/04\/coima-acquisisce-la-sede-di-boehringer-italia-a-milano_598c43be-f79e-473c-af58-91751189162d.html\" target=\"_blank\" rel=\"noopener\">HANDLE<\/a>).<\/p>\n<p>Covivio has signed two new pre-letting agreements with Gruppo Orsero and another Italian industrial company, for 4,500 m2, reaching the 100% pre-letting of the office spaces of Building D of Symbiosis, in Milan, three months before the end of the jobs. The multi-tenant building has a total area of over 18,000 m2. Thanks to the two new agreements, Covivio has completed \u201cthe leasing of the multi-tenant building, already chosen as their headquarters by important multinationals, such as Boehringer Ingelheim\u201d. (<a href=\"https:\/\/www.covivio.eu\/en\/wp-content\/uploads\/sites\/3\/2021\/07\/PR-Symbiosis.pdf\" target=\"_blank\" rel=\"noopener\">Covivio press release<\/a>)<\/p>\n<p>Furthermore, The Bunch, with its partners Prima Pagina and Lateral, was awarded the social communication and PR of the German pharmaceutical company Boehringer Ingelheim, after a tender that involved several structures.<\/p>\n<p>The Boehringer Ingelheim Group was founded in 1885 by Albert Boehringer (1861-1939) in Ingelheim near Mainz in the Rhineland. Thanks to his skill and intuition, he begins to extract tartaric acid from the pomace, used in the food industry. It is a very successful idea, which marks the beginning of a great entrepreneurial story which, starting from 28 collaborators in Nieder-Ingelheim, now has branches all over the world.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>Note:\u00a0<em>Multi-tenancy. Being a neologism, there is no Italian equivalent for the term &quot;Tenant&quot;. Literally, the term indicates a tenant and in the specific case a &quot;co-owner&quot;, such as those who acquire the property right (timeshare) of a structure. In a formal sense, it can take the meaning of lessee.<\/em><\/p>\n<p><em>It could make the idea something like &quot;condominium architecture&quot; (but, like many other Italian terms, the original language is used, ie English). Multitenancy saves costs. In general, multi-tenant office buildings with all modern conveniences have a higher rental price than single-tenant offices. The big difference lies in the additional costs consisting, for example, of small maintenance, cleaning costs, gas, water and electricity costs, internet and telephony, general meeting rooms, etc.<\/em><\/p>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>Coima Sgr ha perfezionato l&#8217;acquisizione, attraverso il fondo Coima Opportunity Fund II, di un complesso immobiliare sito in Milano, in angolo tra Via Giovanni Lorenzini e Via Ercole Marelli, che comprende 7 immobili per una superficie commerciale complessiva pari a 19.500 metri quadrati e che attualmente ospita la sede italiana della multinazionale farmaceutica Boehringer Ingelheim. &hellip;<\/p>","protected":false},"author":4,"featured_media":60277,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[47],"class_list":["post-60274","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-big-pharma"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/60274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=60274"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/60274\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/60277"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=60274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=60274"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=60274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}